63 results
8-K
EX-99.1
BCDA
BioCardia, Inc.
19 Dec 23
Other Events
7:00am
patients treated with culture expanded MSCs or dedicated controls using the Helix delivery system with no observed treatment emergent serious adverse events
424B5
BCDA
BioCardia, Inc.
17 Nov 23
Prospectus supplement for primary offering
5:25pm
Our second therapeutic platform is our investigational culture expanded bone marrow derived allogenic or "off the shelf" mesenchymal cell therapy
8-K
EX-99.1
BCDA
BioCardia, Inc.
9 Aug 23
Biocardia Reports Second Quarter 2023 Business Highlights and Financial Results
4:08pm
) in ischemic heart failure using the Company’s proprietary Helix™ delivery system encompassing 93 patients treated with culture expanded MSCs
424B5
5rc dskie2xvb9s
22 Jun 23
Prospectus supplement for primary offering
8:33am
8-K
EX-99.1
oe0 zkt8o9
6 Dec 22
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
7:01am
8-K
EX-99.1
erj1nsp co
9 Nov 22
Biocardia Reports Third Quarter 2022 Business Highlights and Financial Results
4:07pm
8-K
EX-99.1
q9l5imt449d46p
10 Aug 22
Biocardia Reports Second Quarter 2022 Business Highlights and Financial Results
4:06pm
8-K
EX-99.1
gshkk73q2o7t
11 May 22
Biocardia Reports First Quarter 2022 Business Highlights and Financial Results
4:06pm
424B5
r2mn14oyy8pe614yg
12 Apr 22
Prospectus supplement for primary offering
8:01am
8-K
EX-99.1
hid1h06l3 jot40t4
29 Mar 22
Biocardia Reports 2021 Financial Results and Recent Business Highlights
4:07pm